Daily Roundup

BIO.ASX VR1.ASX HZN.ASX NEU.ASX ACE.ASX

Biome Launches First Human Clinical Trial on BMB18 Probiotic

Biome Australia Limited has announced a significant milestone in its research and development efforts. The company has submitted ethics approval and registered its first human clinical trial on its proprietary probiotic strain, Lactobacillus plantarum BMB18 (BMB18). This randomized, double-blind, placebo-controlled trial will recruit 240 participants to investigate the efficacy of BMB18 in improving digestive, sleep, and mood issues.

The successful completion of in vitro research has demonstrated BMB18's ability to effectively modulate immune responses, reduce inflammation, and maintain intestinal barrier integrity. Positive clinical validation of this proprietary strain is expected to strengthen Biome's competitive position, support new product development, and expand the company's addressable market opportunities in the lucrative gut health category.

Vection Technologies Reports Strong Q4 Cash Receipts

Vection Technologies, a leading provider of digital transformation solutions, has delivered a strong trading update for the current quarter. The company has reported record cash receipts of approximately $14 million, representing a remarkable 115% year-over-year increase. This result highlights the sustained demand for Vection's offerings across the Defence, AI, Healthcare, Industrial, and Retail sectors.

Furthermore, Vection's Total Contracted Value has reached around $27 million, and its 3-year pipeline has grown to a record $50 million. These figures reflect the company's robust commercial position and its ability to convert multi-year frameworks, especially in the defence and enterprise AI markets.

Echelon Signs Term Sheet to Unlock NT Growth

Echelon Resources Limited has signed a non-binding, conditional term sheet with the Northern Territory's Power and Water Corporation for the sale of gas from the Mereenie and Palm Valley fields through to the end of 2034. This agreement will enable the drilling of four new development wells, adding up to 13.3 PJ of additional gas supply (net to Echelon).

The arrangement is expected to significantly increase conventional gas output from the Amadeus Basin and help address the current supply constraints in the Northern Territory. Echelon's CEO, Andrew Jefferies, expressed excitement about this near-term growth opportunity, stating that the new wells will keep the Territory powered with clean-burning gas.

Central Petroleum and Horizon Oil Secure Long-Term Gas Supply Deals

In a related development, Central Petroleum and its Mereenie and Palm Valley Joint Venture partners have also entered into a binding Letter of Intent with the Northern Territory's Power and Water Corporation. This agreement supports an accelerated 4-well drilling program and long-term gas supply agreements for up to 25.5 PJ (Central share) through 2034.

Horizon Oil and its Mereenie Joint Venture partners have signed a similar binding Letter of Intent with the Power and Water Corporation. This arrangement will facilitate an accelerated 2-well drilling program at the Mereenie field and long-term gas supply agreements through 2034.

These agreements are designed to quickly deliver significant new gas volumes to the Northern Territory, enhancing supply security for the region.

Neuren Pharmaceuticals' Partner Acadia Receives FDA Approval for New Rett Syndrome Treatment

Neuren Pharmaceuticals has announced that its partner, Acadia Pharmaceuticals, has received FDA approval for DAYBUE® STIX (trofinetide), a new powder formulation of trofinetide for the treatment of Rett syndrome in adult and pediatric patients. This new formulation offers Rett syndrome patients and their caregivers additional flexibility and choice regarding the dose volume and taste of their DAYBUE treatment.

Neuren, which has granted an exclusive worldwide license to Acadia for the development and commercialization of trofinetide, will receive royalties on all net sales of the product and is eligible for additional milestone payments.

Acusensus Raises $30 Million in Successful Placement

Acusensus Ltd, a technology company developing AI-enabled road safety solutions, has completed a $30 million placement. The company issued 20 million new shares at $1.50 per share, with strong support from both existing and new investors.

The proceeds from the placement will be used to fund Acusensus' business development, contract mobilization, product innovation, and other growth initiatives. The company has also secured its first major US contract in Connecticut, worth an estimated $34 million over 5 years, and expanded existing contracts in Queensland and Western Australia.

Acusensus is well-positioned for continued growth, with a strengthened balance sheet and a robust pipeline of domestic and international opportunities.